By Tali Rackner
Norfolk, Va., June 7 – Bank of Montreal priced $212,000 of 8.4% autocallable cash-settled notes with fixed interest payments due May 31, 2017 linked to the iShares Nasdaq Biotechnology exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.
Interest will be payable monthly.
If the fund finishes above the 110% call level on any monthly call date beginning Dec. 27, the notes will be called at par plus the coupon.
The payout at maturity will be par unless the fund finishes below its initial price and closes below the 75% trigger level on any trading day during the life of the notes, in which case investors will be fully exposed to the loss.
BMO Capital Markets Corp. is the agent.
Issuer: | Bank of Montreal
|
Issue: | Autocallable cash-settled notes with fixed interest payments
|
Underlying fund: | iShares Nasdaq Biotechnology ETF
|
Amount: | $212,000
|
Maturity: | May 31, 2017
|
Coupon: | 8.4%, payable monthly
|
Price: | Par of $1,000
|
Payout at maturity: | Par unless fund closes below 75% trigger price at any time during life of the notes and finishes below initial price, in which case full exposure to fund’s decline from its initial price
|
Call: | At par plus the coupon if fund closes above 110% call level on any monthly call date beginning Dec. 27
|
Initial price: | $273.69
|
Trigger price: | $205.27, 75% of initial level
|
Pricing date: | May 26
|
Settlement date: | May 31
|
Agent: | BMO Capital Markets Corp.
|
Fees: | 0.6%
|
Cusip: | 06367TDY3
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.